

**Oligo(dT) Generated Complementary DNA from *Schistosoma haematobium*, Egyptian Strain, Miracidia**

**Catalog No. NR-49833**

This reagent is the tangible property of the U.S. Government.

**For research use only. Not for human use.**

**Contributor and Manufacturer:**

Michael H. Hsieh, M.D., Ph.D., Stirewalt Endowed Director, Biomedical Research Institute, Rockville, Maryland, USA (NIH-NIAID Contract HHSN272201000051)

**Product Description:**

Complementary DNA (cDNA) was synthesized from total RNA extracted from *Schistosoma haematobium* (*S. haematobium*), Egyptian strain, miracidia, using the ProtoScript® II First Strand cDNA Synthesis Kit (New England BioLabs®). The kit provides an anchored oligo-[d(T)<sub>23</sub>VN] primer which forces the primer to anneal to the beginning of the polyA tail increasing the yield of 3' end poly(A)-primed cDNAs.<sup>1</sup>

The Egyptian strain of *S. haematobium* was originally isolated circa 1950 from an unknown location in Egypt. The laboratory stock of the Egyptian strain of *S. haematobium* was later mixed with an isolate that was thought to be obtained from Abrawash (Cairo) by the Naval Medical Research Unit III, in 1977, to produce the current Egyptian strain of *S. haematobium*.<sup>2</sup> *S. haematobium* is a species of trematode worm which causes the chronic parasitic disease Schistosomiasis.

**Material Provided:**

Each vial of NR-49833 contains approximately 1 µg of cDNA in DNase/RNase-free distilled water. The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

**Packaging/Storage:**

NR-49833 was packaged in cryovials. The product is provided frozen and should be stored at -20°C or colder upon arrival. Freeze-thaw cycles should be minimized.

**Citation:**

Acknowledgment for publications should read "The following reagent was provided by the NIAID Schistosomiasis Resource Center for distribution through BEI Resources, NIAID, NIH: Oligo(dT) Generated Complementary DNA from *Schistosoma haematobium*, Egyptian Strain, Miracidia, NR-49833."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services,

Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Nam, D. K., et al. "Oligo(dT) Primer Generates a High Frequency of Truncated cDNAs Through Internal Poly(A) Priming During Reverse Transcription." Proc. Natl. Acad. Sci. USA 99 (2002): 6152-6156. PubMed: 11972056.
2. Matthew S. Tucker, Head Schistosomiasis Laboratory and Principal Investigator (prior to 2015), Biomedical Research Institute, Personal Communication.

ATCC® is a trademark of the American Type Culture Collection.

